Hormone replacement therapy (HRT) helps with a wide range of symptoms caused by falling estrogen levels during menopause. Its most dramatic effect is on hot flashes and night sweats, where it can reduce both the frequency and intensity of episodes by nearly 90%, often within the first month. But the benefits extend well beyond temperature regulation, reaching into bone health, mood, sexual function, body composition, and vaginal and urinary health.
Hot Flashes and Night Sweats
Hot flashes and night sweats are the most common reason people start HRT, and they’re also where the therapy has its strongest track record. Estrogen stabilizes the body’s internal thermostat, which becomes erratic as natural hormone levels drop. That near-90% reduction in both frequency and severity is more effective than any other available treatment for these symptoms, and most people notice a difference within weeks rather than months.
Night sweats specifically can wreck sleep quality, creating a cascade of daytime fatigue, irritability, and difficulty concentrating. By addressing the root cause, HRT often improves sleep indirectly, even though it isn’t a sleep medication.
Vaginal and Urinary Health
Estrogen plays a direct role in maintaining the tissue lining the vagina and urinary tract. After menopause, that tissue thins, loses elasticity, and produces less natural lubrication. The vaginal pH shifts, making infections more common. These changes are collectively called genitourinary syndrome of menopause, and unlike hot flashes, they don’t improve on their own over time. They typically get worse.
HRT promotes regrowth and blood flow to vaginal tissue, normalizes pH, and increases lubrication. It can also reduce the frequency of recurrent urinary tract infections. For people whose symptoms are primarily vaginal or urinary rather than whole-body, low-dose local estrogen (a vaginal cream, ring, or tablet) can deliver these benefits without the systemic exposure of a pill or patch.
Bone Strength and Fracture Prevention
Estrogen is essential for maintaining bone density. Without it, bones lose mineral content faster than they can rebuild, which is why osteoporosis rates climb sharply after menopause. HRT doesn’t just slow that process. It preserves bone microarchitecture and significantly reduces fracture risk at every major site: vertebral fractures drop by about 40%, hip fractures by 30%, and overall osteoporotic fractures by 20 to 30% compared to calcium and vitamin D alone.
In the Women’s Health Initiative, one of the largest clinical trials on this topic, HRT prevented an estimated 47 fragility fractures per 10,000 women per year. This makes it one of the most effective tools for fracture prevention in postmenopausal women, particularly those who can’t tolerate other bone medications.
Mood, Anxiety, and Emotional Stability
The perimenopausal years bring a measurably higher risk of depression and anxiety, driven largely by fluctuating estrogen levels rather than the absolute drop. Estrogen influences several brain chemicals tied to mood regulation, and when levels swing unpredictably, emotional stability can suffer.
A meta-analysis of 14 randomized trials found that estrogen therapy provides meaningful benefits for perimenopausal depression, either on its own or alongside other treatments. The mechanism appears to work by replacing erratic hormone swings with stable levels. In one controlled study using combined estrogen-progesterone therapy over three 28-day cycles, the treatment group showed significant improvements in both positive and negative emotional states compared to placebo. The overall effectiveness rate was 96% in the treated group versus 87% in the placebo group.
It’s worth noting that these mood benefits are best documented during perimenopause, when hormone fluctuations are most volatile. The evidence for mood improvement in women many years past menopause is less clear.
Sexual Desire and Comfort
Menopause affects sexual health from multiple directions. Vaginal dryness makes intercourse painful, and hormonal shifts can dampen desire itself. HRT addresses both. The tissue changes described above directly reduce pain during sex, and estrogen therapy at sufficient levels has been shown to increase sexual desire in four out of five clinical trials that measured it.
For people whose libido doesn’t respond to estrogen alone, adding low-dose testosterone can make a significant difference. Ten out of twelve studies found that testosterone enhanced estrogen’s effect on sexual desire. This combination isn’t universally prescribed, but it’s an option worth discussing if desire remains low after starting standard HRT.
Body Composition and Metabolic Health
Menopause triggers a shift in where your body stores fat. Even without weight gain, fat tends to migrate toward the abdomen, wrapping around internal organs as visceral fat. This type of fat is metabolically active and drives up the risk of insulin resistance, type 2 diabetes, and cardiovascular disease.
HRT users have measurably less visceral fat than non-users, along with lower fasting blood sugar and lower fasting insulin levels. The relationship between visceral fat and insulin sensitivity also appears to be more favorable in HRT users: at higher levels of abdominal fat, women on HRT maintained better insulin sensitivity than those not on therapy.
Heart Health: Timing Matters
The relationship between HRT and heart disease has been one of the most debated topics in menopause medicine. The short version: timing is everything. Starting HRT within 10 years of menopause onset or before age 60 is associated with a 32% lower risk of coronary heart disease and a 39% lower risk of death from any cause compared to placebo. Estrogen appears to slow the progression of early-stage atherosclerosis, the buildup of plaque in artery walls.
Starting HRT more than 10 years after menopause, or after age 60, flips the equation. At that point, the absolute risks of heart disease, stroke, and blood clots increase, and the cardiovascular benefits largely disappear. This “timing hypothesis” is now well supported by major trials and is reflected in current clinical guidelines.
Patches vs. Pills: A Meaningful Difference
How you take HRT changes its risk profile, particularly for blood clots. Oral estrogen passes through the liver first, which triggers increased production of clotting factors. Transdermal estrogen (patches, gels, or sprays) absorbs directly into the bloodstream and skips that liver activation entirely.
The difference is substantial. Across multiple studies, oral estrogen roughly tripled or quadrupled blood clot risk compared to non-users, while transdermal estrogen showed no significant increase at all. For women who carry genetic clotting mutations like Factor V Leiden, the gap is even more dramatic: oral HRT increased clot risk 25-fold in one study, while transdermal HRT raised it only fourfold. This is the clearest and most consistent safety difference between the two delivery methods, and it’s one reason many clinicians now favor patches or gels as the default.
What HRT Does Not Help With
Despite earlier hopes, HRT does not appear to prevent cognitive decline or reduce the risk of dementia. A 2025 systematic review in The Lancet Healthy Longevity found no significant association between HRT use and dementia risk in any direction, regardless of when it was started, how long it was used, or what type was prescribed. Some large observational studies actually suggest combined HRT may slightly increase dementia risk with long-term use. Current guidelines from both North American and UK medical bodies advise against using HRT for dementia prevention.
Who Benefits Most
The benefit-risk balance is most favorable for women under 60, or within 10 years of menopause onset, who have bothersome symptoms and no contraindications such as a history of breast cancer, blood clots, or liver disease. For this group, HRT addresses the core symptoms of menopause while offering protective effects on bones, metabolism, and cardiovascular health.
There is no fixed time limit on how long you can use HRT. Current guidelines from the North American Menopause Society recommend that longer-term use should be tied to ongoing symptoms, with periodic reevaluation. The decision to continue, adjust, or stop is individual, based on whether the benefits you’re experiencing still outweigh the risks for your specific health profile.